pharma · Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation · Myelodysplastic Syndrome · PMVP
PMV Pharmaceuticals
PMV Pharmaceuticals clinical programs — 6 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- PRINCETON, NJ, USA
- Employees
- 4
- Programs
- 6
- Drugs
- 5
- Patents
- 11
PMV Pharmaceuticals projects
6 ClinicalTrials.gov programs sponsored by PMV Pharmaceuticals.
PMV Pharmaceuticals has 6 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
PC14586
PMV Pharmaceuticals
Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation
1 trial -
rezatapopt
PMV Pharmaceuticals
Advanced Solid Tumor
1 trial -
Azacitidine
PMV Pharmaceuticals
Myelodysplastic Syndrome
1 trial -
PC14586
PMV Pharmaceuticals
Healthy Volunteers
3 trials -
[14C]-PC14586
PMV Pharmaceuticals
Healthy Male Volunteers
1 trial -
metformin hydrochloride 500 mg tablet
PMV Pharmaceuticals
TP53 Y220C Mutation
1 trial
Frequently asked questions
How many clinical projects does PMV Pharmaceuticals have?
6 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.